United States

Navidea Biopharmaceuticals Inc (NAVB.A)

NAVB.A on American Stock Exchange

11:16am EDT
Change (% chg)

$0.02 (+2.36%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for NAVB.A


Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.... (more)
No analyst recommendations are available for NAVB.A.


Beta: 0.19
Market Cap(Mil.): $132.72
Shares Outstanding(Mil.): 155.75
Dividend: --
Yield (%): --


  NAVB.A Industry Sector
P/E (TTM): -- 46.09 36.24
EPS (TTM): -0.14 -- --
ROI: -- 3.17 13.93
ROE: -- 3.16 14.87

BRIEF-Navidea Biopharma says appoints Michael Goldberg, M.D. as CEO

* Says appoints Michael M. Goldberg, M.D. president and chief executive officer

Sep 26 2016

BRIEF-Navidea achieves $1 mln in Lymphoseek commercial milestones

* Navidea achieves $1 million in Lymphoseek commercial milestones

Sep 22 2016

BRIEF-Navidea enters into letter of intent with cardinal health for sale of Lymphoseek in North America

* Navidea Biopharmaceuticals enters into letter of intent with cardinal health for the sale of Lymphoseek in North America

Sep 06 2016

BRIEF-Navidea Biopharmaceuticals Q2 loss per share $0.04

* Continuing to explore alternative financing arrangements in order to refinance crg debt

Aug 04 2016

BRIEF-Navidea gets IRB nod for Lymphoseek rheumatoid arthritis trial protocol

* Navidea receives IRB approval for its Lymphoseek rheumatoid arthritis clinical trial protocol

Jul 19 2016

BRIEF-Navidea Biopharma says continuing to explore alternative financing to refinance some debt

* Received letter dated May 31, 2016 from Capital Royalty Partners II L.P and Capital Royalty Partners II Parallel Fund A L.P. (CRG)

Jun 02 2016

BRIEF-Navidea says received unsolicited offer to refinance CRG loan facility

* Received an unsolicited offer to refinance entire existing CRG loan facility

May 23 2016

BRIEF-Navidea reports Q1 loss per share of $0.02

* Expects to begin grant-funded phase 1/2 evaluation of lymphoseek - iv in kaposi's sarcoma patients in second half of 2016

May 17 2016

BRIEF-Navidea Biopharmaceuticals says received demand for arbitration from CEO Ricardo Gonzalez

* On May 12, received a demand for arbitration from Ricardo Gonzalez, company's chief executive officer - sec filing

May 13 2016

BRIEF-Navidea Biopharmaceuticals files for non-timely 10-Q

* Navidea Biopharmaceuticals Inc files for non-timely 10-Q Source text: http://1.usa.gov/1T9HjVJ Further company coverage:

May 10 2016


  Price Chg
General Electric Company (GE.N) $28.81 -0.12
Bayer AG (BAYGn.DE) €91.50 +0.45
Bayer AG (BAYE.F) -- --
Eli Lilly and Co (LLY.N) $77.73 +0.16

Earnings vs. Estimates